Koers Essex Bio-Technology Limited Deutsche Boerse AG
Aandelen
EB51
KYG312371035
Farmaceutische producten
Omzet 2022 | 1,32 mld. 169 mln. 156 mln. | Omzet 2023 | 1,71 mld. 218 mln. 202 mln. | Marktkapitalisatie | 1,41 mld. 181 mln. 167 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 225 mln. 28,8 mln. 26,58 mln. | Nettowinst (verlies) 2023 | 275 mln. 35,2 mln. 32,48 mln. | EV/omzet 2022 | 1,78 x |
Nettoliquiditeiten 2022 | 53,76 mln. 6,88 mln. 6,35 mln. | Nettoliquiditeiten 2023 | 221 mln. 28,29 mln. 26,1 mln. | EV/omzet 2023 | 0,7 x |
K/w-verhouding 2022 |
11
x | K/w-verhouding 2023 |
5,31
x | Werknemers | 1.481 |
Dividendrendement 2022 |
1,55% | Dividendrendement 2023 |
3,61% | Vrij verhandelbaar | 45,97% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Hai Zhou Fang
CEO | Chief Executive Officer | 58 | 31-07-00 |
Qi Xue
CTO | Chief Tech/Sci/R&D Officer | 63 | 09-04-18 |
Hian Leng Ngiam
BRD | Director/Board Member | 40 | 01-01-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mia Je Ngiam
FOU | Founder | 70 | 01-02-99 |
Lai Man Yau
BRD | Director/Board Member | 60 | 01-01-01 |
Mee Mooi Yeow
BRD | Director/Board Member | 72 | 30-09-04 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,57% | 96,72 mld. | |
+5,66% | 41,43 mld. | |
-12,66% | 32,7 mld. | |
+80,99% | 29,06 mld. | |
-15,49% | 15,38 mld. | |
-8,69% | 12,97 mld. | |
-12,22% | 11,36 mld. | |
+183,25% | 9,9 mld. | |
+3,60% | 8,93 mld. |